Roger Jeffs Sells 6,428 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 6,428 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $62.18, for a total value of $399,693.04. Following the completion of the sale, the chief executive officer owned 1,041,667 shares of the company’s stock, valued at approximately $64,770,854.06. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

• On Tuesday, May 26th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $60.38, for a total value of $1,509,500.00.
• On Thursday, May 21st, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $61.13, for a total value of $1,528,250.00.
• On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $58.65, for a total value of $1,466,250.00.
• On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $57.04, for a total value of $1,426,000.00.
• On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $56.29, for a total value of $1,407,250.00.
• On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total value of $1,037,500.00.
• On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total value of $1,052,250.00.
• On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total value of $1,002,500.00.
• On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
• On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.

Liquidia Stock Performance

Shares of Liquidia stock opened at $61.79 on Friday. The firm has a market cap of $5.49 billion, a P/E ratio of 441.35 and a beta of 0.41. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $63.46. The stock’s fifty day moving average price is $44.53 and its 200-day moving average price is $38.47.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, equities research analysts expect that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of LQDA. Covestor Ltd lifted its holdings in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Liquidia by 7.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after acquiring an additional 422 shares during the period. Quantinno Capital Management LP lifted its holdings in Liquidia by 3.6% in the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after acquiring an additional 589 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia in the fourth quarter valued at approximately $25,000. Finally, ProShare Advisors LLC lifted its holdings in Liquidia by 7.1% in the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after acquiring an additional 775 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

LQDA has been the topic of several research reports. Needham & Company LLC raised their price target on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Wells Fargo & Company raised their price target on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. HC Wainwright raised their price target on Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Oppenheimer raised their price target on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research note on Thursday, March 12th. Finally, Wall Street Zen upgraded Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).